(Q41727411)

8 October 2017

1 reference

title

PSA for outcome prediction and posttreatment evaluation following radiation for prostate cancer: do we know how to use it? (English)

1 reference

8 October 2017

Kuban DA

1

1 reference

PubMed ID

9516587

8 October 2017

El-Mahdi AM

series ordinal

2

1 reference

PubMed ID

9516587

8 October 2017

Schellhammer PF

series ordinal

3

1 reference

8 October 2017

1 April 1998

1 reference

Seminars in Radiation Oncology

8 October 2017

1 reference

8 October 2017

8

1 reference

8 October 2017

2

1 reference

8 October 2017

72-80

1 reference

How to use prostate-specific antigen

8 October 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2898%2980002-7

7 January 2021

Prostate-specific antigen and radiation therapy for clinically localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2898%2980002-7

7 January 2021

An enhanced prognostic system for clinically localized carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2898%2980002-7

7 January 2021

Prostate-specific antigen for pretreatment prediction and posttreatment evaluation of outcome after definitive irradiation for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2898%2980002-7

7 January 2021

Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2898%2980002-7

7 January 2021

Localized prostate cancer treated by external-beam radiotherapy alone: serum prostate-specific antigen--driven outcome analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2898%2980002-7

7 January 2021

Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2898%2980002-7

7 January 2021

Re: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2898%2980002-7

7 January 2021

Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2898%2980002-7

7 January 2021

Equivalent biochemical failure-free survival after external beam radiation therapy or radical prostatectomy in patients with a pretreatment prostate specific antigen of > 4-20 ng/ml

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2898%2980002-7

7 January 2021

Early stage prostate cancer treated with radiation therapy: stratifying an intermediate risk group

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2898%2980002-7

7 January 2021

Prostate-specific antigen cancer volume: a significant prognostic factor in prostate cancer patients at intermediate risk of failing radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2898%2980002-7

7 January 2021

Prostate cancer volume adds significantly to prostate-specific antigen in the prediction of early biochemical failure after external beam radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2898%2980002-7

7 January 2021

Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. III. Radiation treated patients

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2898%2980002-7

7 January 2021

Prostate Specific Antigen in the Management of Patients with Localized Adenocarcinoma of the Prostate Treated with Primary Radiation Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2898%2980002-7

7 January 2021

Prostate-specific antigen as a predictor of radiotherapy response and patterns of failure in localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2898%2980002-7

7 January 2021

A model of prostatic carcinoma tumor kinetics based on prostate specific antigen levels after radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2898%2980002-7

7 January 2021

A prospective study of prostate specific antigen levels in patients receiving radiotherapy for localized carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2898%2980002-7

7 January 2021

The prognostic significance of a single serum prostate-specific antigen value beyond six months after radiation therapy for adenocarcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2898%2980002-7

7 January 2021

Changes in immunohistochemical staining of PSA, PAP, and TURP-27 following irradiation therapy for clinically localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2898%2980002-7

7 January 2021

The effect of pelvic radiation therapy on serum levels of prostate specific antigen

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2898%2980002-7

7 January 2021

Serum prostate-specific antigen after radiation therapy for clinically localized prostate cancer: Prognostic implications

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2898%2980002-7

7 January 2021

Assessing the variability of outcome for patients treated with localized prostate irradiation using different definitions of biochemical control

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2898%2980002-7

7 January 2021

Prostate specific antigen following radiotherapy for local prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2898%2980002-7

7 January 2021

Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: clinical observations

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2898%2980002-7

7 January 2021

Prostate specific antigen doubling time and disease relapse after radiotherapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2898%2980002-7

7 January 2021

Linear regressive analysis using prostate-specific antigen doubling time for predicting tumor biology and clinical outcome in prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2898%2980002-7

7 January 2021

Analysis of independent variables affecting survival after recurrence of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2898%2980002-7

7 January 2021

Treatment of clinical local failure after radiation therapy for prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2898%2980002-7

7 January 2021

Time to second prostate-specific antigen failure is a surrogate endpoint for prostate cancer death in a prospective trial of therapy for localized disease

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2898%2980002-7

7 January 2021

MRC study: when to commence treatment in advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2898%2980002-7

7 January 2021

Salvage radical prostatectomy: outcome measured by serum prostate specific antigen levels

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2898%2980002-7

7 January 2021

125iodine reimplantation for locally progressive prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2898%2980002-7

7 January 2021

10.1016/S1053-4296(98)80002-7

Identifiers

DOI

1 reference

8 October 2017

1 reference

PubMed ID

9516587